%A Wang Ying, Li Xuyuan, Lin Yingcheng %T Advance of treatment in hormone refractory prostate cancer %0 Journal Article %D 2014 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2014.01.018 %P 56-59 %V 41 %N 1 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9281.shtml} %8 2014-01-08 %X Treatment with docetaxel and prednisone every 3 weeks is preferred in hormone refractory prostate cancer. In recent years, a number of clinical trials are held to assess the efficacy of docetaxelbased regimens combined with antiangiogenesis agents, firstline treatment of androgen ablation, and salvage therapy after chemotherapy failure with docetaxel. For hormone refractory prostate cancer, abiraterone can be used as the first choice, while, enzalutamide can be used as another endocrine therapy for patients who tolerate with docetaxel. However, chemotherapy combined with targeted drugs still cannot challenge the firstline treatment status of docetaxel plus prednisone.